Non-Hodgkin's lymphoma is the fifth most common cancer in the United
States. As biomedical knowledge regarding recombinant DNA technology
has advanced, a number of targeted treatments have been developed,
including monoclonal antibodies.
Monoclonal antibodies have exhibited promising results in the routine
and experimental treatment of patients with non-Hodgkin's lymphoma.
Particularly interesting is the development of radioimmunoconjugates:
monoclonal antibodies conjugated to radioactive molecules.
Radioimmunotherapy provides the option of targeting specific radiation
to tumor cells while sparing normal cells from the toxic effects of
radiation. Current clinical trials of radioimmunotherapy are focused on
monoclonal antibodies conjugated with either radioactive yttrium or
The presentations in this collection will provide an overview of the
evolution of monoclonal antibody therapy in the treatment of
non-Hodgkin's lymphoma, discuss current trials examining the safety and
efficacy of radioimmunotherapy, and assess the potential impact of
radioimmunotherapy on the treatment of patients with non-Hodgkin's
These proceedings were published in Volume 1, Issue 1, of Bloodline Reviews. You can download a PDF version of the complete issue or use the below links to access the content on the web.
Participants and Presentations:
Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: An Overview
Presenter: Brian K. Link, MD
Radioimmunotherapy Agents: What They Are and How They Work
Presenter: Gregory A. Wiseman, MD
Early Clinical Experience with Yttrium-Labeled Radioimmunotherapy in Patients with Low-Grade Non-Hodgkin's Lymphoma
Presenter: Leo I. Gordon, MD
Radioimmunotherapy in Patients with Non-Hodgkin's Lymphoma Refractory to Chemotherapy and Immunotherapy
Presenter: Thomas E. Witzig, MD
Radioimmunotherapy in Hematologic Malignancies: Future Directions
Presenter: Bruce D. Cheson, MD